The shingles vaccine market is not a monolith; it is a complex ecosystem divided into distinct segments that cater to different patient needs. In 2026, the primary segmentation is between "Recombinant Subunit Vaccines" and "Live-Attenuated Vaccines." While the latter is being phased out in many Western nations due to lower efficacy, it still maintains a presence in specific niche markets where...